CD274 and triple-negative breast carcinoma: PD-1/PD-L1 pathway inhibitors have achieved great success in clinical trials for patients with various types of cancer, and have been approved for use in clinical practice for patients with several cancers, including triple-negative breast cancer (TNBC) [7,12,13,14,15].